CareDx R&D Spending Growth & History (CDNA)
CareDx's r&d spending was $71.4M for fiscal 2025.
View full CareDx company overviewCareDx annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $71.4M | −$1.1M | −1.49% |
| 2024 | 2024-12-31 | $72.5M | −$9.9M | −12.02% |
| 2023 | 2023-12-31 | $82.4M | −$8.0M | −8.81% |
| 2022 | 2022-12-31 | $90.4M | $13.9M | +18.12% |
| 2021 | 2021-12-31 | $76.5M | $27.6M | +56.36% |
| 2020 | 2020-12-31 | $48.9M | $18.2M | +59.36% |
| 2019 | 2019-12-31 | $30.7M | $16.2M | +111.60% |
| 2018 | 2018-12-31 | $14.5M | $2.1M | +17.16% |
| 2017 | 2017-12-31 | $12.4M | $3,000 | +0.02% |
| 2016 | 2016-12-31 | $12.4M | $3.1M | +32.70% |
| 2015 | 2015-12-31 | $9.3M | $5.5M | +142.67% |
| 2014 | 2014-12-31 | $3.8M | $670,000 | +21.10% |
| 2013 | 2013-12-31 | $3.2M | −$1.6M | −33.16% |
| 2012 | 2012-12-31 | $4.8M | — | — |
CareDx quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $22.4M | $5.5M | +32.95% |
| Q1 2026 | 2026-03-31 | $21.4M | $2.9M | +15.61% |
| Q4 2025 | 2025-12-31 | $19.3M | $2.7M | +16.16% |
| Q3 2025 | 2025-09-30 | $16.8M | −$717,000 | −4.10% |
| Q2 2025 | 2025-06-30 | $16.8M | −$2.9M | −14.54% |
| Q1 2025 | 2025-03-31 | $18.5M | −$187,000 | −1.00% |
| Q4 2024 | 2024-12-31 | $16.6M | −$2.2M | −11.74% |
| Q3 2024 | 2024-09-30 | $17.5M | −$1.5M | −7.97% |
| Q2 2024 | 2024-06-30 | $19.7M | −$540,000 | −2.67% |
| Q1 2024 | 2024-03-31 | $18.7M | −$5.6M | −23.18% |
| Q4 2023 | 2023-12-31 | $18.8M | −$4.7M | −20.11% |
| Q3 2023 | 2023-09-30 | $19.0M | −$3.3M | −14.82% |
| Q2 2023 | 2023-06-30 | $20.2M | −$2.4M | −10.60% |
| Q1 2023 | 2023-03-31 | $24.4M | $2.5M | +11.32% |
| Q4 2022 | 2022-12-31 | $23.6M | $1.5M | +6.91% |
| Q3 2022 | 2022-09-30 | $22.3M | $2.9M | +14.75% |
| Q2 2022 | 2022-06-30 | $22.6M | $3.6M | +18.89% |
| Q1 2022 | 2022-03-31 | $21.9M | $5.9M | +36.72% |
| Q4 2021 | 2021-12-31 | $22.0M | $8.7M | +65.45% |
| Q3 2021 | 2021-09-30 | $19.4M | $7.0M | +55.84% |
| Q2 2021 | 2021-06-30 | $19.0M | $5.9M | +44.99% |
| Q1 2021 | 2021-03-31 | $16.0M | $6.0M | +59.83% |
| Q4 2020 | 2020-12-31 | $13.3M | $4.4M | +48.95% |
| Q3 2020 | 2020-09-30 | $12.5M | $4.0M | +46.39% |
| Q2 2020 | 2020-06-30 | $13.1M | $5.5M | +72.07% |
| Q1 2020 | 2020-03-31 | $10.0M | $4.4M | +78.36% |
| Q4 2019 | 2019-12-31 | $8.9M | $5.2M | +136.54% |
| Q3 2019 | 2019-09-30 | $8.5M | $4.7M | +120.29% |
| Q2 2019 | 2019-06-30 | $7.6M | $4.1M | +118.25% |
| Q1 2019 | 2019-03-31 | $5.6M | $2.2M | +66.69% |
| Q4 2018 | 2018-12-31 | $3.8M | $754,000 | +24.90% |
| Q3 2018 | 2018-09-30 | $3.9M | $909,000 | +30.72% |
| Q2 2018 | 2018-06-30 | $3.5M | $378,000 | +12.12% |
| Q1 2018 | 2018-03-31 | $3.4M | $85,000 | +2.59% |
| Q4 2017 | 2017-12-31 | $3.0M | −$125,000 | −3.96% |
| Q3 2017 | 2017-09-30 | $3.0M | $29,000 | +0.99% |
| Q2 2017 | 2017-06-30 | $3.1M | −$25,000 | −0.80% |
| Q1 2017 | 2017-03-31 | $3.3M | $124,000 | +3.93% |
| Q4 2016 | 2016-12-31 | $3.2M | $449,000 | +16.61% |
| Q3 2016 | 2016-09-30 | $2.9M | $232,000 | +8.60% |
| Q2 2016 | 2016-06-30 | $3.1M | $633,000 | +25.22% |
| Q1 2016 | 2016-03-31 | $3.2M | $1.7M | +122.31% |
| Q4 2015 | 2015-12-31 | $2.7M | $1.4M | +108.32% |
| Q3 2015 | 2015-09-30 | $2.7M | $1.7M | +160.42% |
| Q2 2015 | 2015-06-30 | $2.5M | $1.7M | +216.92% |
| Q1 2015 | 2015-03-31 | $1.4M | $701,000 | +97.36% |
| Q4 2014 | 2014-12-31 | $1.3M | — | — |
| Q3 2014 | 2014-09-30 | $1.0M | $368,000 | +55.09% |
| Q2 2014 | 2014-06-30 | $792,000 | −$54,000 | −6.38% |
| Q1 2014 | 2014-03-31 | $720,000 | — | — |
| Q3 2013 | 2013-09-30 | $668,000 | — | — |
| Q2 2013 | 2013-06-30 | $846,000 | — | — |
CareDx r&d spending trends
Over the last five fiscal years, CareDx's r&d spending increased from $48.9M to $71.4M, a change of $22.5M. The latest reported quarter, Q2 2026, shows $22.4M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CareDx source filings ↗